J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast.
Sandra I. McCoy,William C. Miller,Pia D. M. MacDonald,Christopher B. Hurt,Peter A. Leone,Joseph J. Eron,Ronald P. Strauss +6 more
TL;DR: A qualitative study of 24 HIV infected persons attending a Southeastern HIV clinic who presented with clinically advanced illness found the primary barrier to HIV testing prior to diagnosis was perception of risk; consequently, most participants were diagnosed after the onset of clinical symptoms.
Journal ArticleDOI
Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients
Robin Wood,Keikawus Arastéh,Hans Jürgen Stellbrink,Eugenio Teofilo,François Raffi,Richard B. Pollard,Joseph J. Eron,Jane Yeo,Judith Millard,Mary Beth Wire,Odin J. Naderer +10 more
TL;DR: The protease inhibitor GW433908 delivered comparable plasma amprenvir concentrations to those delivered by amprenavir 1,200 mg BID, and in combination with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a 4-week period.
Journal ArticleDOI
Comparison of NucliSens and Roche Monitor Assays for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma
John R. Dyer,Christopher D. Pilcher,Robin Shepard,Jody Schock,Joseph J. Eron,Susan A. Fiscus +5 more
TL;DR: Both had similar linearity and sensitivity over most of the dynamic range of the assays, although the Monitor assay was superior at the low range of RNA values while the NucliSens assay was more consistent at higher RNA values.
Journal ArticleDOI
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Alan L. Landay,Barbara A. da Silva,Martin S. King,Mary Albrecht,Constance A. Benson,Joseph J. Eron,Marshall J. Glesby,Roy M. Gulick,Charles B. Hicks,Harold A. Kessler,Robert L. Murphy,Melanie A. Thompson,A. Clinton White,Peter R. Wolfe,Florence I. McMillan,George J. Hanna +15 more
TL;DR: The receipt of a lopinavir-ritonavir-based regimen resulted in ongoing immune reconstitution through 6 years of therapy in a cohort of HIV-1-infected, antiretroviral-naive subjects with suppressed HIV- 1 RNA levels.
Journal ArticleDOI
Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
TL;DR: The majority of patients with TC-DR have extensive antiretroviral exposure, particularly to non-HAART regimens, whereas HAART initiators are at low risk of acquiringTC-DR during a median of 4 years of follow-up.